<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00693186</url>
  </required_header>
  <id_info>
    <org_study_id>HXV01C</org_study_id>
    <nct_id>NCT00693186</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA</brief_title>
  <official_title>An Open-label, Randomised, Controlled, Multi-centre Study of the Immunogenicity and Safety of a Booster Dose of Two Different Hepatitis B Vaccines to Explore the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children Previously Vaccinated at About 3, 5 and 11 to 13 Months of Age With Either HEXAVAC® or INFANRIX®-HEXA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

        -  To describe in subjects vaccinated with 3 doses of HEXAVAC® or 3 doses of INFANRIX®-HEXA
           during the first two years of life the percentage of subjects with an anti-HBs antibody
           titre ≥10 mIU/mL 1 month after a booster dose of either HBVaxPRO® 5 µg or Engerix B® 10
           µg .

      Secondary objectives:

        -  Additional immunogenicity assessments

        -  Standard safety assessment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with anti-HBs antibody titres &gt;=10 mIU/mL measured at 1 month post-booster dose</measure>
    <time_frame>28 to 42 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">410</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBVaxPRO® 5 µg / 0.5 mL</intervention_name>
    <description>5 µg / 0.5 mL</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix B® 10 µg / 0.5 mL</intervention_name>
    <description>10 µg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy child of 4 to 7 years of age of either gender,

          -  Child vaccinated with 2 doses of HEXAVAC® during the first 6 months of life and with a
             3rd dose of HEXAVAC® before the end of the second year of life or Child vaccinated
             with 2 doses of INFANRIX®-HEXA during the first 6 months of life and with a 3rd dose
             of INFANRIX®-HEXA before the end of the second year of life,

          -  Informed consent form signed by the parent(s) or by the legal representative.

          -  Parent(s) or legal representative able to understand and comply with the study
             procedures.

        Exclusion Criteria:

          -  Any recent (&lt;=3 days) history of febrile illness prior to vaccination,

          -  Receipt of more than 3 doses of any Hepatitis B containing vaccine, either alone or in
             any combination,

          -  History of clinical or serological-confirmed diagnosis of infection due to hepatitis
             B,

          -  History or current close contact with known carriers of hepatitis B virus,

          -  Prior known sensitivity/allergy to any component of the study vaccines,

          -  Any known blood dyscrasias, leukemia, lymphomas of any type, or other malignant
             neoplasms affecting the haematopoietic and lymphatic systems,

          -  Any severe thrombocytopenia or any other coagulation disorder that would
             contraindicate intramuscular injection,

          -  Any immune impairment or humoral/cellular deficiency or depressed immunity,

          -  Any recent (&lt;=30 days) long-term (&gt;=14 days) administration of systemic
             corticosteroids given daily or on alternate days at &gt;=20 mg/day prednisone equivalent
             or scheduled administration through Visit 2,

          -  Any receipt (&lt;=3 months) of immunoglobulins or blood-derived products, or scheduled
             administration through Visit 2,

          -  Any recent (&lt;=14 days) receipt of an inactivated vaccine or scheduled administration
             through Visit 2,

          -  Any recent (&lt;=28 days) receipt of a live vaccine or scheduled administration through
             Visit 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unità Operativa Semplice di Epidemiologia (UOSE)</name>
      <address>
        <city>Quarto</city>
        <state>Napoli</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda per i Servizi Sanitari n. 5 &quot;Bassa Friulana&quot;</name>
      <address>
        <city>Latisana</city>
        <state>Udine</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore di Modica - Via Resistenza Partigiana (c/o Ospedale Maggiore)</name>
      <address>
        <city>Modica</city>
        <zip>97015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AUSL n. 7 di Ragusa Servizio di Epidemiologia Via G. Di Vittorio 59/c</name>
      <address>
        <city>Ragusa</city>
        <zip>97100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Prevenzione Servizio di Igiene Pubblica</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2008</study_first_submitted>
  <study_first_submitted_qc>June 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <last_update_submitted>September 8, 2017</last_update_submitted>
  <last_update_submitted_qc>September 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

